To determine the impact of cSCC-GEP test results on management decisions made by dermatologists for cSCC patients.

TissueCypher risk stratified BE patients with a community-based diagnosis of LGD with an accuracy comparable to three renowned expert pathologists.

Expert panel of 9 dermatologists developed 29 clinical scenarios creating an evidence based framework for AUC recommendations for integration of melanoma GEP tests into clincial practice

Review the current literature and establish the level of evidence for a cutaneous melanoma 31-GEP test.

Multi center study establishing appropriate use criteria for determining risk of recurrence in patients with tumors >0.3mm in thickness

TissueCypher identifies NDBE patients who are at increased risk for progression to HGD/EAC and may benefit from increased surveillance or early intervention.

Independent, prospective study with over 3.5 years of follow-up, showing results consistent with previous validation studies with GEP class score as statistically associated with MSS, DMFS and RFS.

Clinical validation study of the 23-GEP in lesions with clinical outcomes and follow-up data

Multicentre evaluation the early prognostic performance of a genetic signature in a multicentre prospectively evaluated cohort.

Gene expression profile class and node status stratified tumors into significantly different 5-year survival groups by Kaplan-Meier method and both were independent predictors of recurrence in multivariate analysis.

Multicenter prospective study in T1-T2 tumors showed combining GEP with Breslow thickness and age can provide a more precise determination of SLN positivity risk.

Discovery of reduced RFS for patients with thin tumors and Class 2B biology and cumulative validation cohort for DecisionDx-Melanoma. DecisionDx-Melanoma was the strongest independent predictor of RFS, DMFS and MSS.